KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Total Liabilities (2016 - 2025)

Amgen has reported Total Liabilities over the past 17 years, most recently at $81.9 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $81.9 billion for Q4 2025, down 4.69% from a year ago — trailing twelve months through Dec 2025 was $81.9 billion (down 4.69% YoY), and the annual figure for FY2025 was $81.9 billion, down 4.69%.
  • Total Liabilities for Q4 2025 was $81.9 billion at Amgen, up from $80.5 billion in the prior quarter.
  • Over the last five years, Total Liabilities for AMGN hit a ceiling of $90.9 billion in Q4 2023 and a floor of $51.5 billion in Q2 2021.
  • Median Total Liabilities over the past 5 years was $81.2 billion (2025), compared with a mean of $73.1 billion.
  • Biggest five-year swings in Total Liabilities: surged 47.94% in 2023 and later decreased 5.46% in 2024.
  • Amgen's Total Liabilities stood at $54.5 billion in 2021, then increased by 12.84% to $61.5 billion in 2022, then surged by 47.94% to $90.9 billion in 2023, then fell by 5.46% to $86.0 billion in 2024, then dropped by 4.69% to $81.9 billion in 2025.
  • The last three reported values for Total Liabilities were $81.9 billion (Q4 2025), $80.5 billion (Q3 2025), and $80.5 billion (Q2 2025) per Business Quant data.